The present study showed that osimertinib‐resistant, EGFR‐mutant NSCLC cells with EMT features release exosomes encapsulating resistant components with increased levels of miR‐210, thereby inducing EMT changes and acquired drug resistance in osimertinib‐sensitive cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.